Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III Registration Study of Topsalysin in Patients with Intermediate Risk Localized Prostate Cancer

Trial Profile

A Phase III Registration Study of Topsalysin in Patients with Intermediate Risk Localized Prostate Cancer

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 21 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Topsalysin (Primary)
  • Indications Prostate cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Sophiris Bio
  • Most Recent Events

    • 21 Oct 2019 According to a Sophiris Bio media release, if the proposed study were positive and the safety profile were to continue as observed in clinical trials to date, this single study has the potential to provide the clinical data to support regulatory approval in both the US and Europe.
    • 21 Oct 2019 According to a Sophiris Bio media release, the Phase 3 study design agreed upon with the FDA is consistent with the design previously agreed upon with the European Medicines Agency, as reported in June of this year.In addition, the FDA has indicated that in order to receive approval, Sophiris will evaluate all patients that progress to alternative treatments for an additional 12 months, for a total of 24 months of data, post the administration of study drug.
    • 21 Oct 2019 According to a Sophiris Bio media release, following an End of Phase 2/ Pre-Phase 3 meeting with the United States Food and Drug Administration (FDA), there is agreement regarding the design of a single Phase 3 clinical trial to evaluate the potential of topsalysin as a targeted focal therapy to treat patients with intermediate risk localized prostate cancer.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top